Investor Relations

Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

Upcoming Event

Sickle Cell Disease (SCD) Community Town Hall

Latest Financial Results

Q3 2019

Quarter Ended Jun 30, 2019

Latest Annual Filing

For Fiscal Year Ending Sep 30, 2018

Investor Contact Information

Company

Emmaus Life Sciences, Inc.
21250 Hawthorne Blvd.
Suite 800
Torrance, CA 90503
T: 310-214-0065
info@emmausmedical.com

Investor Relations

PondelWilkinson Inc.
Roger Pondel / Laurie Berman
T: 310-279-5980
EMMA@pondel.com

Transfer Agent

American Stock Transfer & Trust Company
Brooklyn, NY
T: 800-937-5449 / 718-921-8124
help@astfinancial.com

Some of the statements contained on this website, which are not historical facts, are forward-looking statements, which by their nature involve risks and uncertainties.  For further information on factors that could affect Emmaus Life Sciences, please refer to the company’s periodic filings with the Securities and Exchange Commission.

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.